These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 10537438)

  • 1. Health economics in HIV disease. A review of the European literature.
    Youle M; Trueman P; Simpson K
    Pharmacoeconomics; 1999; 15 Suppl 1():1-12. PubMed ID: 10537438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health economics in HIV disease.
    Youle M
    Antivir Ther; 1999; 4 Suppl 3():43-7. PubMed ID: 16021870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment and care costs of people with HIV infection or AIDS: development of a standardised cost framework for Europe.
    Tolley K; Gyldmark M
    Health Policy; 1993 Apr; 24(1):55-70. PubMed ID: 10125812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.
    Lacey L; Youle M; Trueman P; Staszewski S; Schrappe M; Behrens M
    Pharmacoeconomics; 1999; 15 Suppl 1():39-53. PubMed ID: 10537441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health economics: potential applications in HIV/AIDS control in Africa.
    Kirigia JM; Sambo LG; Anikpo E; Karisa E; Mwabu G
    Afr J Health Sci; 2005; 12(1-2):1-12. PubMed ID: 17298133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine.
    Biddle AK; Simpson KN
    Value Health; 2000; 3(3):186-201. PubMed ID: 16464183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis.
    Baggaley RF; Irvine MA; Leber W; Cambiano V; Figueroa J; McMullen H; Anderson J; Santos AC; Terris-Prestholt F; Miners A; Hollingsworth TD; Griffiths CJ
    Lancet HIV; 2017 Oct; 4(10):e465-e474. PubMed ID: 28768604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost of depression in Europe.
    Sobocki P; Jönsson B; Angst J; Rehnberg C
    J Ment Health Policy Econ; 2006 Jun; 9(2):87-98. PubMed ID: 17007486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The costs of treating HIV-infected children in Abidjan, Ivory Coast, 1996-1997].
    Giraudon I; Leroy V; Msellati P; Elenga N; Ramon R; Welffens-Ekra C; Dabis F
    Sante; 1999; 9(5):277-81. PubMed ID: 10657769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the variation in costs among HIV primary care providers.
    Gilman BH; Green JC
    AIDS Care; 2008 Oct; 20(9):1050-6. PubMed ID: 18825514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic antiretroviral drugs and HIV care: An economic review.
    Yazdanpanah Y; Schwarzinger M
    Med Mal Infect; 2016 Mar; 46(2):67-71. PubMed ID: 26905394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Looking down the barrel of a cannon: the potential economic costs of HIV/AIDS in Papua New Guinea.
    Hauquitz AC
    P N G Med J; 2004; 47(1-2):39-49. PubMed ID: 16496514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.
    Langtry HD; Palmer KJ; Benfield P
    Pharmacoeconomics; 1993 Apr; 3(4):309-37. PubMed ID: 10146993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic impact of delaying or preventing AIDS in persons with HIV.
    Pinkerton SD; Holtgrave DR
    Am J Manag Care; 1999 Mar; 5(3):289-98. PubMed ID: 10351025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008.
    Beck EJ; Harling G; Gerbase S; DeLay P
    Curr Opin HIV AIDS; 2010 May; 5(3):215-24. PubMed ID: 20539077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economics and European Renal Best Practice--is it time to bring health economics into evidence-based guideline production in Europe?
    Haller MC; Vanholder R; Oberbauer R; Zoccali C; Van Biesen W
    Nephrol Dial Transplant; 2014 Nov; 29(11):1994-7. PubMed ID: 24009293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.